Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nitric oxide synthase 2, inducible | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | cytochrome P450 reductase | 0.0032 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0016 | 0 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0032 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0029 | 0.7743 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0032 | 1 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0032 | 1 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0029 | 0.7743 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0032 | 1 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.002 | 0.2407 | 0.2407 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0032 | 1 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0032 | 1 | 0.5 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0032 | 1 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0032 | 1 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0032 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0032 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0032 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0032 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0016 | 0.0151 | 0.0151 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0032 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0032 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0032 | 1 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0032 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0032 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0032 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0016 | 0 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.002 | 0.2407 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0032 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0032 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (binding) | = 0.02 uM | Inhibition of human iNOS expressed in human HEK293 cells assessed as nitrite accumulation after 18 hrs by 2,3-diaminonapthalene assay | ChEMBL. | 21986586 |
EC50 (binding) | > 100 uM | Inhibition of human nNOS expressed in HEK293 cells assessed as inhibition ionomycin-induced nitric oxide production incubated for 24 hrs measured after 18 hrs of ionomycin challenge by 2,3-diaminonaphthalene assay | ChEMBL. | 21986586 |
EC50 (binding) | > 100 uM | Inhibition of human eNOS expressed in HEK293 cells assessed as inhibition A23187-induced nitric oxide production incubated for 24 hrs measured after 18 hrs of A23187 challenge by 2,3-diaminonaphthalene assay | ChEMBL. | 21986586 |
Inhibition (binding) | < 50 % | Inhibition of human eNOS expressed in HEK293 cells assessed as inhibition A23187-induced nitric oxide production at 100 uM incubated for 24 hrs measured after 18 hrs of A23187 challenge by 2,3-diaminonaphthalene assay | ChEMBL. | 21986586 |
Inhibition (binding) | < 50 % | Inhibition of human nNOS expressed in HEK293 cells assessed as inhibition ionomycin-induced nitric oxide production at 100 uM incubated for 24 hrs measured after 18 hrs of ionomycin challenge by 2,3-diaminonaphthalene assay | ChEMBL. | 21986586 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.